Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.16 AUD
Change Today -0.005 / -3.12%
Volume 34.0K
CIR On Other Exchanges
As of 1:20 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

circadian technologies ltd (CIR) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/12/14 - A$0.28
52 Week Low
12/1/14 - A$0.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

circadian technologies ltd (CIR) Related Businessweek News

No Related Businessweek News Found

circadian technologies ltd (CIR) Details

Circadian Technologies Limited develops and commercializes therapies for eye and cancer diseases in Australia. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and R3 targets, which are used for the treatment of diseases associated with angiogenesis. The company’s lead molecule includes OPT-302, a soluble form of VEGFR-3 that is used for the treatment of neovascular age-related macular degeneration and dry-eye diseases. Its product pipeline also comprises VGX-100, a monoclonal antibody for VEGF-C that has completed Phase IA/IB clinical study in advanced cancer patients; and IMC-3C5, an antibody targeting VEGFR-3. In addition, the company develops CUPGUIDE, a diagnostic test, which is used in the treatment of cancers of unknown primary; and VEGF-D LAM Diagnostic, an ELISA-based diagnostic test to measure circulating levels of VEGF-D, as well as offers VEGF-C/VEGF-D reagents under the Vegenics brand name. Further, it develops novel forms of insulin through DiMiTech Platform that is used for the treatment of diabetes. Circadian Technologies Limited is based in South Yarra, Australia.

circadian technologies ltd (CIR) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$270.4K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$24.5K
Head of Intellectual Property
Total Annual Compensation: A$191.0K
Head of CMC Development
Total Annual Compensation: A$182.2K
Head of Clinical Development and Director of ...
Total Annual Compensation: A$181.9K
Compensation as of Fiscal Year 2014.

circadian technologies ltd (CIR) Key Developments

Circadian Technologies Limited Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Circadian Technologies Limited reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenue of $127,889 against $149,625 a year ago. Total revenue was $366,215 against $396,901 a year ago. Loss before income tax was $4,291,672 against $3,440,922 a year ago. Loss for period was $3,018,683 against $1,587,808 a year ago. Loss for the period attributable to owners of the parent was $2,940,460 against $1,577,531 a year ago. Basic and diluted loss per share was 4.58 cents against 3.24 cents a year ago. Net cash flows used in operating activities was $4,057,760 against $3,123,679 a year ago.

Circadian Technologies Limited Announces Formation of Clinical Advisory Board

Circadian Technologies Limited announced the formation of a Clinical Advisory Board (CAB) focused on the development of its VEGF-C/-D ‘trap’, OPT-302, for the treatment of ophthalmic diseases including wet age-related macular degeneration (wet AMD). The CAB will provide insight into the regulatory and clinical development strategy for OPT-302. The CAB will initially be comprised of four members, including: Pravin Dugel, MD – Managing Partner of Retinal Consultants of Arizona, founding member of the Spectra Eye Institute and Clinical Professor, Department of Ophthalmology, Keck School of Medicine, University of Southern California Mark Gillies, MBBS, PhD - Professor of Retinal Therapeutics, Save Sight Institute, University of Sydney; Peter Campochiaro, MD - Professor of Ophthalmology and Neuroscience, Johns Hopkins Wilmer Eye Institute; Kameran Lashkari, MD – Associate Professor, Schepens Eye Research Institute at Harvard Medical School/Massachusetts Eye and Ear.

Circadian Technologies Limited, Annual General Meeting, Nov 18, 2014

Circadian Technologies Limited, Annual General Meeting, Nov 18, 2014., at 11:00 AUS Eastern Standard Time. Location: Computershare Conference Centre, Yarra Falls. Agenda: To consider the annual report for 2014; to consider the election of director; to consider the re-election of director; to consider the adoption of remuneration report; to consider the issue of shares under a placement; to consider the ratification of shares issued under a placement issue of options to the corporate advisor; to consider the long term incentive plan; to consider the issue of options to Megan Baldwin under the LTIP; and to consider the approval of non-executive director share and option plan.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CIR:AU A$0.16 AUD -0.005

CIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CIR.
View Industry Companies

Industry Analysis


Industry Average

Valuation CIR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.4x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CIRCADIAN TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at